[Federal Register: May 23, 2002 (Volume 67, Number 100)]
[Notices]
[Page 36202-36203]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr23my02-77]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
[[Page 36203]]
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Methods for Predicting Properties of Molecules
Richard Beger, Jon G. Wilkes (FDA).
DHHS Reference No. E-297-01/0 filed 07 Mar 2002.
Licensing Contact: Dale Berkley; 301/496-7735 ext. 223; e-mail:
berkleyd@od.nih.gov.
The invention is a method for predicting the biological, chemical,
and physical properties of molecules from their chemical shift data
using through-bond and spatial distance connectivity patterns. In this
method, predicted NMR chemical shift data that has already been
structurally assigned in the process of developing the spectral
predictions is used to construct a model that predicts biological,
chemical and physical properties of the molecule. Since the structural
assignments are only used to established molecular distance
connectivity relationships, models can be developed for sets of
molecules that do not share a common backbone geometry. In model
development and use there is no molecular docking step. These models
correlate particular molecules with desired ``endpoints,'' including
receptor-ligand binding, cancer effects, drug absorption and others.
The new technique is a three dimensional Quantitative Structure Data-
Activity Relationship (QSDAR) based on the spectrum-activity leg in the
triangular structure-spectrum-activity relationship. The invention
provides a quantitative relationship between spectra and certain
properties or activities of the molecule, and will have important
implications in the search for new therapeutic drugs. 3D-QSDAR
Modelling is a very rapid objective process compared to conventional
predictive methods. In comparable published results, the 3D-QSDAR model
quality consistently exceeds that of conventional QSAR predictive
methods.
GP41 Inhibitor
G. Marius Clore et al. (NIDDK).
DHHS Reference No. E-252-01/0 filed 17 Dec 2001.
Licensing Contact: Carol Salata; 301/496-7735 ext. 232; e-mail:
salatac@od.nih.gov.
The technology relates to a chimeric molecule, NCCG-
gp41, in which the internal trimeric helical coiled-coil of the
ectodomain of gp41 is fully exposed and stabilized by both fusion to a
minimal ectodomain core of gp41 and by engineered intersubunit
disulfide bonds. NCCG-gp41 inhibits HIV envelope mediated
cell fusion at nonomolar concentrations with an IC50 of 16
nM. It is proposed that NCCG-gp41 targets the exposed C-
terminal region of the gp41 ectodomain in its pre-hairpin intermediate
state, thereby preventing the formation of the fusogenic form of the
gp41 ectodomain that comprises a highly stable trimer of hairpins
arranged in a six-helix bundle. NCCG-gp41 has potential as
(a) an HIV therapeutic agent that inhibits cell entry; (b) as an AIDS
vaccine and; (c) as a component of a high throughput screening assay
for small molecule inhibitors of HIV envelope mediated cell fusion.
Antibodies have been raised against NCCG-gp41 that inhibit
HIV envelope mediated cell fusion. This invention is further described
in J. Biol. Chem. 2001 Aug 3;276(31):29485-9.
Immunization for Ebola Virus Infection
Gary Nabel (NIAID/VRC), Anthony Sanchez.
Serial No. 60/068,655 filed 23 Dec 1997; Serial No. 09/913,909 filed 17
Aug 2001.
Licensing Contact: Carol Salata; 301/496-7735 ext. 232; e-mail:
salatac@od.nih.gov.
The Ebola viruses, and the genetically related Marburg virus, are
filoviruses associated with outbreaks of highly lethal hemorrhagic
fever in humans and primates in North America, Europe and Africa. This
invention relates to Ebola virus vaccines comprising nucleic acid
molecules encoding Ebola viral proteins (including the transmembrane
form of the viral Glycoprotein (GP), the secreted form of the viral
Glycoprotein (sGP) and the viral nucleoprotein (NP)). The nucleic acid
molecules of the vaccines of the invention encode structural gene
products of any Ebola viral strain including the Zaire, Sudan, Ivory
Coast and Reston strains as well as the genetically related Marburg
virus strains. The invention relates to the nucleic acid vaccines as
well as the corresponding protein vaccines. The invention also provides
methods for immunizing a subject against disease caused by infection
with Ebola virus.
Dated: May 3, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 02-13018 Filed 5-22-02; 8:45 am]
BILLING CODE 4140-01-P